{"entity":"regeneron-pharmaceuticals","id":"ent_regeneron-pharmaceuticals","name":"Regeneron Pharmaceuticals","wikidata":"Q7308054","page":"https://asof.is/record/regeneron-pharmaceuticals","summary":"As of November 12, 2025, Regeneron Pharmaceuticals was an American pharmaceutical company, headquartered in Tarrytown. Its CEO was Leonard S. Schleifer, since 1988. It reported revenue of $14.20B for the period ended December 31, 2024.","title":"Regeneron Pharmaceuticals: CEO Leonard S. Schleifer","key_facts":[{"label":"CEO","value":"Leonard S. Schleifer","note":"since 1988","claim":"clm_31DC6D4DC56C"},{"label":"CFO","value":"Christopher Fenimore","claim":"clm_0D057E1B2379"},{"label":"Headquarters","value":"Tarrytown","claim":"clm_4EBDB058F389"},{"label":"Revenue","value":"$14.20B","recorded":"14,202,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_EE95AAD2339E"},{"label":"Ticker","value":"REGN · Nasdaq","claim":"clm_CE8DC6176B9E"}],"faq":[{"question":"Who is the CEO of Regeneron Pharmaceuticals?","answer":"Leonard S. Schleifer, since 1988, as the AsOf record states with its sources."},{"question":"Where is Regeneron Pharmaceuticals headquartered?","answer":"Tarrytown."},{"question":"What is Regeneron Pharmaceuticals's revenue?","answer":"$14.20B for the period ended December 31, 2024."}],"as_of":"2025-11-12","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/regeneron-pharmaceuticals/ceo","md":"https://asof.is/record/regeneron-pharmaceuticals/ceo.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/ceo"},{"predicate":"chair","page":"https://asof.is/record/regeneron-pharmaceuticals/chair","md":"https://asof.is/record/regeneron-pharmaceuticals/chair.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/chair"},{"predicate":"cfo","page":"https://asof.is/record/regeneron-pharmaceuticals/cfo","md":"https://asof.is/record/regeneron-pharmaceuticals/cfo.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/regeneron-pharmaceuticals/headquarters","md":"https://asof.is/record/regeneron-pharmaceuticals/headquarters.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/regeneron-pharmaceuticals/revenue","md":"https://asof.is/record/regeneron-pharmaceuticals/revenue.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/revenue"},{"predicate":"net_income","page":"https://asof.is/record/regeneron-pharmaceuticals/net_income","md":"https://asof.is/record/regeneron-pharmaceuticals/net_income.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/regeneron-pharmaceuticals/operating_income","md":"https://asof.is/record/regeneron-pharmaceuticals/operating_income.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/regeneron-pharmaceuticals/quarterly_revenue","md":"https://asof.is/record/regeneron-pharmaceuticals/quarterly_revenue.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/quarterly_revenue"}],"products":[],"coverage":{"entity":"regeneron-pharmaceuticals","name":"Regeneron Pharmaceuticals","kind":"organization","sources":[{"source":"wikidata","item":"Q7308054","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":872589,"ticker":"REGN","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":515,"open":23,"retracted":0,"first":"1988-01-01","predicates":{"revenue":{"claims":18,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":53,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":53,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":53,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":72,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"total_assets":{"claims":67,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":53,"open":1,"kind":"fact"},"research_and_development":{"claims":18,"open":1,"kind":"fact"},"net_income":{"claims":18,"open":1,"kind":"fact"},"total_equity":{"claims":72,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"shares_outstanding":{"claims":9,"open":1,"kind":"fact"},"operating_income":{"claims":18,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"ceo":{"claims":1,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"agreement":{"claims":1,"open":1,"kind":"event"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"ticker":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":515,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_5CC511D1F933","predicate":"cash_and_equivalents","value":"2,506,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,506,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_5CC511D1F933, https://asof.is/claim/clm_5CC511D1F933, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_5CC511D1F933","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B18C1963BC40","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_31DC6D4DC56C","predicate":"ceo","value":"Leonard S. Schleifer","valid_from":"1988-01-01","valid_to":null,"published":"2026-04-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals ceo: Leonard S. Schleifer\", as of 1988-01-01. Claim clm_31DC6D4DC56C, https://asof.is/claim/clm_31DC6D4DC56C, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm.","url":"https://asof.is/claim/clm_31DC6D4DC56C","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-04-24T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"Leonard S. Schleifer, M.D., Ph.D., 73, founded the Company in 1988 and has been a director and its President and Chief Executive Officer since its inception.","url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm"}},{"id":"clm_0D057E1B2379","predicate":"cfo","value":"Christopher Fenimore","valid_from":"2024-02-01","valid_to":null,"published":"2026-04-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cfo: Christopher Fenimore\", as of 2024-02-01. Claim clm_0D057E1B2379, https://asof.is/claim/clm_0D057E1B2379, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm.","url":"https://asof.is/claim/clm_0D057E1B2379","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-04-24T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Effective February 2024, the board appointed Christopher Fenimore to succeed Robert E. Landry as the Company’s Chief Financial Officer upon Mr. Landry’s retirement.","url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm"}},{"id":"clm_E84D1B159AB1","predicate":"chair","value":"Leonard S. Schleifer","valid_from":"2023-06-09","valid_to":null,"published":"2023-04-17","recorded":"2026-11-12","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals chair: Leonard S. Schleifer\", as of 2023-06-09. Claim clm_E84D1B159AB1, https://asof.is/claim/clm_E84D1B159AB1, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm.","url":"https://asof.is/claim/clm_E84D1B159AB1","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K Item 5.02","published_at":"2023-04-17T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-12","quote":"Effective upon the expiration of Dr. Vagelos’s term, the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm"}},{"id":"clm_0D4E584017A3","predicate":"cik","value":"0000872589","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cik: 0000872589\", undated. Claim clm_0D4E584017A3, https://asof.is/claim/clm_0D4E584017A3, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_0D4E584017A3","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2BC841F0E994","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals fiscal year end: 12-31\", undated. Claim clm_2BC841F0E994, https://asof.is/claim/clm_2BC841F0E994, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_2BC841F0E994","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4EBDB058F389","predicate":"headquarters","value":"Tarrytown","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals headquarters: Tarrytown\", undated. Claim clm_4EBDB058F389, https://asof.is/claim/clm_4EBDB058F389, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_4EBDB058F389","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_60E05C2B8B5C","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals listed on: Nasdaq\", undated. Claim clm_60E05C2B8B5C, https://asof.is/claim/clm_60E05C2B8B5C, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_60E05C2B8B5C","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4E27594C511A","predicate":"net_income","value":"4,412,600,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 4,412,600,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_4E27594C511A, https://asof.is/claim/clm_4E27594C511A, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_4E27594C511A","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7514724ED5E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-05"}},{"id":"clm_398CD3D76930","predicate":"operating_income","value":"3,990,700,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 3,990,700,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_398CD3D76930, https://asof.is/claim/clm_398CD3D76930, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_398CD3D76930","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1B456AFB0CC5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-05"}},{"id":"clm_75B9586D5FEE","predicate":"quarterly_net_income","value":"1,460,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,460,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_75B9586D5FEE, https://asof.is/claim/clm_75B9586D5FEE, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_75B9586D5FEE","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_55728063B1D6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_0F41A2F44A01","predicate":"quarterly_operating_income","value":"1,026,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,026,800,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_0F41A2F44A01, https://asof.is/claim/clm_0F41A2F44A01, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_0F41A2F44A01","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6BF4C3658A74","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_F00F9DA4362C","predicate":"quarterly_research_and_development","value":"1,475,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,475,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_F00F9DA4362C, https://asof.is/claim/clm_F00F9DA4362C, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_F00F9DA4362C","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D76E4D0088C5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_471EC2DBAE0B","predicate":"quarterly_revenue","value":"3,754,300,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,754,300,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_471EC2DBAE0B, https://asof.is/claim/clm_471EC2DBAE0B, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_471EC2DBAE0B","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_89291214D4AA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_0230630DE966","predicate":"registrant_name","value":"REGENERON PHARMACEUTICALS, INC.","valid_from":"1995-07-26","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals registrant name: REGENERON PHARMACEUTICALS, INC.\", as of 1995-07-26. Claim clm_0230630DE966, https://asof.is/claim/clm_0230630DE966, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_0230630DE966","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_C301E7CAF361","predicate":"research_and_development","value":"5,132,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 5,132,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_C301E7CAF361, https://asof.is/claim/clm_C301E7CAF361, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_C301E7CAF361","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1819F20C7CC4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-05"}},{"id":"clm_EE95AAD2339E","predicate":"revenue","value":"14,202,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 14,202,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_EE95AAD2339E, https://asof.is/claim/clm_EE95AAD2339E, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_EE95AAD2339E","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E5421E95D3E6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-05"}},{"id":"clm_24C3500A1DEF","predicate":"shares_outstanding","value":"93,955,110 shares","valid_from":"2012-07-13","valid_to":null,"published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 93,955,110 shares\", as of 2012-07-13. Claim clm_24C3500A1DEF, https://asof.is/claim/clm_24C3500A1DEF, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_24C3500A1DEF","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-07-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-07-25"}},{"id":"clm_BAC78AB8CD88","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_BAC78AB8CD88, https://asof.is/claim/clm_BAC78AB8CD88, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_BAC78AB8CD88","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2EE7611EC44C","predicate":"state_of_incorporation","value":"NY","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals state of incorporation: NY\", undated. Claim clm_2EE7611EC44C, https://asof.is/claim/clm_2EE7611EC44C, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_2EE7611EC44C","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_CE8DC6176B9E","predicate":"ticker","value":"REGN","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals ticker: REGN\", undated. Claim clm_CE8DC6176B9E, https://asof.is/claim/clm_CE8DC6176B9E, accessed 2026-11-12. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_CE8DC6176B9E","accessed":"2026-11-12"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_A47C41C5A48C","predicate":"total_assets","value":"40,169,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 40,169,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_A47C41C5A48C, https://asof.is/claim/clm_A47C41C5A48C, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_A47C41C5A48C","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CFD74D844717","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_CF9BA729AF1E","predicate":"total_equity","value":"30,957,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 30,957,800,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_CF9BA729AF1E, https://asof.is/claim/clm_CF9BA729AF1E, accessed 2026-11-12. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_CF9BA729AF1E","accessed":"2026-11-12"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_68C522C0BDED","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-28"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date"}}}